87 related articles for article (PubMed ID: 9816306)
1. Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera.
Trehu EG; Mier JW; Dubois JS; Sorce D; Klempner MS; Epstein M; Dinarello CA; Shapiro L; Kappler K; Ronayne L; Atkins MB
Clin Cancer Res; 1996 Aug; 2(8):1341-51. PubMed ID: 9816306
[TBL] [Abstract][Full Text] [Related]
2. A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor.
McDermott DF; Trehu EG; Mier JW; Sorce D; Rand W; Ronayne L; Kappler K; Clancy M; Klempner M; Atkins MB
Clin Cancer Res; 1998 May; 4(5):1203-13. PubMed ID: 9607578
[TBL] [Abstract][Full Text] [Related]
3. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma.
Du Bois JS; Trehu EG; Mier JW; Shapiro L; Epstein M; Klempner M; Dinarello C; Kappler K; Ronayne L; Rand W; Atkins MB
J Clin Oncol; 1997 Mar; 15(3):1052-62. PubMed ID: 9060545
[TBL] [Abstract][Full Text] [Related]
4. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma.
Margolin K; Atkins M; Sparano J; Sosman J; Weiss G; Lotze M; Doroshow J; Mier J; O'Boyle K; Fisher R; Campbell E; Rubin J; Federighi D; Bursten S
Clin Cancer Res; 1997 Apr; 3(4):565-72. PubMed ID: 9815721
[TBL] [Abstract][Full Text] [Related]
5. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
Schiller JH; Hank JA; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini MR; Wilding G; Sondel PM
Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma.
Atkins MB; Redman B; Mier J; Gollob J; Weber J; Sosman J; MacPherson BL; Plasse T
Clin Cancer Res; 2001 Mar; 7(3):486-92. PubMed ID: 11297238
[TBL] [Abstract][Full Text] [Related]
7. Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody along with interleukin 2 in patients with cancer.
Hank JA; Albertini M; Wesly OH; Schiller JH; Borchert A; Moore K; Bechhofer R; Storer B; Gan J; Gambacorti C
Clin Cancer Res; 1995 May; 1(5):481-91. PubMed ID: 9816007
[TBL] [Abstract][Full Text] [Related]
8. Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity.
Meropol NJ; Porter M; Blumenson LE; Lindemann MJ; Perez RP; Vaickus L; Loewen GM; Creaven PJ; Wilkes KA; Giedlin MA; Caligiuri MA
Clin Cancer Res; 1996 Apr; 2(4):669-77. PubMed ID: 9816217
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma.
Eton O; Rosenblum MG; Legha SS; Zhang W; Jo East M; Bedikian A; Papadopoulos N; Buzaid A; Benjamin RS
Cancer; 2002 Jul; 95(1):127-34. PubMed ID: 12115326
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
12. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma.
Davis ID; Skrumsager BK; Cebon J; Nicholaou T; Barlow JW; Moller NP; Skak K; Lundsgaard D; Frederiksen KS; Thygesen P; McArthur GA
Clin Cancer Res; 2007 Jun; 13(12):3630-6. PubMed ID: 17575227
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.
Gollob JA; Veenstra KG; Parker RA; Mier JW; McDermott DF; Clancy D; Tutin L; Koon H; Atkins MB
J Clin Oncol; 2003 Jul; 21(13):2564-73. PubMed ID: 12829677
[TBL] [Abstract][Full Text] [Related]
14. In vivo effects of recombinant human interleukin-10 on lymphocyte phenotypes and leukocyte activation markers in inflammatory bowel disease.
Dejaco C; Reinisch W; Lichtenberger C; Waldhoer T; Kuhn I; Tilg H; Gasche C
J Investig Med; 2000 Nov; 48(6):449-56. PubMed ID: 11094868
[TBL] [Abstract][Full Text] [Related]
15. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
D'Andrea G; Fennelly D; Norton L; Baselga J; Gilewski T; Hudis C; Moynahan ME; Raptis G; Sklarin N; Surbone A; Theodoulou M; Templeton MA; Yao TJ; Seidman AD
Clin Cancer Res; 1999 Feb; 5(2):275-9. PubMed ID: 10037175
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor (TNF)-alpha-induced interleukin-8 in human blood cultures discriminates neutralization by the p55 and p75 TNF soluble receptors.
Frishman JI; Edwards CK; Sonnenberg MG; Kohno T; Cohen AM; Dinarello CA
J Infect Dis; 2000 Dec; 182(6):1722-30. PubMed ID: 11069245
[TBL] [Abstract][Full Text] [Related]
18. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration.
Suffredini AF; Reda D; Banks SM; Tropea M; Agosti JM; Miller R
J Immunol; 1995 Nov; 155(10):5038-45. PubMed ID: 7594512
[TBL] [Abstract][Full Text] [Related]
19. Overview of interleukin-2 inhalation therapy.
Huland E; Heinzer H; Huland H; Yung R
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S104-12. PubMed ID: 10685669
[TBL] [Abstract][Full Text] [Related]
20. Expansion of activated T-lymphocytes in patients treated with recombinant interleukin 2.
Kolitz JE; Welte K; Wong GY; Holloway K; Merluzzi VJ; Engert A; Bradley EC; Konrad M; Polivka A; Gabrilove JL
J Biol Response Mod; 1987 Aug; 6(4):412-29. PubMed ID: 3498011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]